AstraZeneca partners with insitro on $1.86 billion AI drug discovery deal

On October 15, 2026, U.K. drugmaker AstraZeneca announced a deal valued at up to $1.5 billion with artificial intelligence startup Insitro to discover treatments for cardiometabolic diseases. AstraZeneca will pay Insitro $40 million upfront and up to $1.46 billion in milestone payments, plus potential sales royalties, in exchange for exclusive worldwide rights to resulting drug programs. Insitro will deploy its AI platform using combined datasets to identify root causes of fatty liver disease and cardiomyopathies, while AstraZeneca handles clinical development.

AstraZeneca and Insitro deal details

• ▪The research collaboration between AstraZeneca and Insitro, announced on October 15, 2026, targets metabolic dysfunction-associated steatohepatitis, a fatty liver condition, and cardiomyopathies, which are diseases affecting the heart muscle
• ▪On October 15, 2026, U.K. drugmaker AstraZeneca announced a partnership with artificial intelligence startup Insitro to discover new treatments for cardiometabolic diseases

Financial terms of the partnership

• ▪AstraZeneca agreed to make an upfront payment of $40 million to Insitro for the artificial intelligence drug discovery collaboration announced on October 15, 2026
• ▪Insitro's agreement with AstraZeneca, announced on October 15, 2026, includes performance payments tied to achieving commercial targets, as well as potential royalties based on prospective sales
• ▪Insitro is eligible to receive up to $1.46 billion from AstraZeneca subject to meeting specified drug development targets

Other AI partnerships in pharma

• ▪Swiss pharmaceutical maker Roche agreed earlier in 2026 to build a supercomputer in partnership with technology company Nvidia for artificial intelligence drug discovery
• ▪Last month, pharmaceutical company Novo Nordisk partnered with artificial intelligence laboratory Anthropic to utilize the Claude Science platform for drug research